US warns of drugs in Reumofan dietary supplements

(AP) — The U.S. Food and Drug Administration is warning consumers not to use Reumofan dietary supplements, after receiving reports of bleeding, stroke and death among Americans taking the Mexico-manufactured pills.

Reumofan Plus and Reumofan Plus Premium are marketed as natural remedies for arthritis and muscle pain, but the FDA says the actually contain several prescription drugs.

A chemical analysis by the agency found that Reumofan Plus contains three drugs, including the muscle relaxant methocarbomal and the anti-inflammatory dexamethasone. These drugs can interact with other medications, causing life-threatening side effects in some patients.

The FDA first warned consumers about the products in June, but says complications have continued to be reported.

Reumofan products are manufactured in Mexico by Riger Naturals and sold in the U.S. at retail shops and over the Internet.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

FDA seizes sexual enhancement products

Apr 10, 2008

The U.S. Food and Drug Administration announced the seizure by U.S. marshals of more than 14,000 units of Shangai- and Naturale-brand diet supplements.

FDA cracks down on illegal supplements

Dec 15, 2010

(AP) -- The Food and Drug Administration is cracking down on manufacturers of certain weight loss, body building and sexual enhancement supplements that contain potentially dangerous ingredients.

Recommended for you

Have a cold? Don't ask your doctor for antibiotics

Nov 26, 2014

Antibiotic resistance is a major threat to public health. Resistance makes it harder for physicians to treat infections and can increase the chance patients will die from an infection. What is more, the treatment ...

Powdered measles vaccine found safe in early clinical trials

Nov 25, 2014

A measles vaccine made of fine dry powder and delivered with a puff of air triggered no adverse side effects in early human testing and it is likely effective, according to a paper to be published November 28 in the journal ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.